UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] RSS 2.0 [feed] RSS 1.0 [feed] Atom
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | I | J | K | L | M | P | R | S | T | U | V | W | Y | Z
Number of items: 113.

A

Abdallah, QM; Phillips, RM; Johansson, F; Helleday, T; Cosentino, L; Abdel-Rahman, H; ... Pors, K; + view all (2012) Minor structural modifications to alchemix influence mechanism of action and pharmacological activity. Biochem Pharmacol , 83 (11) 1514 - 1522. 10.1016/j.bcp.2012.02.017.

Adair, JR; Howard, PW; Hartley, JA; Williams, DG; Chester, KA; (2012) Antibody-drug conjugates - a perfect synergy. Expert Opin Biol Ther , 12 (9) 1191 - 1206. 10.1517/14712598.2012.693473.

Aksoy, E; Taboubi, S; Torres, D; Delbauve, S; Hachani, A; Whitehead, MA; ... Vanhaesebroeck, B; + view all (2012) The p110δ isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat Immunol , 13 (11) 1045 - 1054. 10.1038/ni.2426.

Alcolea, MP; Casado, P; Rodríguez-Prados, JC; Vanhaesebroeck, B; Cutillas, PR; (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics , 11 (8) 453 - 466. 10.1074/mcp.M112.017483.

Anthoney, DA; Naik, J; MacPherson, IRJ; Crawford, D; Hartley, JM; Hartley, JA; ... Evans, TRJ; + view all (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer , 12 , Article 536. 10.1186/1471-2407-12-536. Green and gold open access
file

Arkenau, H-T; Saggese, M; Lemech, C; (2012) Advanced gastric cancer: Is there enough evidence to call second-line therapy standard? World Journal of Gastroenterology , 18 (44) 6376 - 6378. 10.3748/wjg.v18.i44.6376. Gold open access

Arkenau, H-T; Saggese, M; Lemech, C; (2012) Dabrafenib mesylate: Serine/threonine-protein kinase B-raf inhibitor oncolytic. Drugs of the Future , 37 (7) 469 - 474. 10.1358/dof.2012.37.7.1820872.

Arkenau, HT; Plummer, R; Molife, LR; Olmos, D; Yap, TA; Squires, M; ... Judson, I; + view all (2012) A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol , 23 (5) 1307 - 1313. 10.1093/annonc/mdr451.

Asghar, U; Meyer, T; (2012) Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol , 56 (3) 686 - 695. 10.1016/j.jhep.2011.07.031.

Aslan, D; Akata, RF; Holme, H; Vulliamy, T; Dokal, I; (2012) Limbal stem cell deficiency in patients with inherited stem cell disorder of dyskeratosis congenita. Int Ophthalmol , 32 (6) 615 - 622. 10.1007/s10792-012-9611-8.

B

Bachner, M; Loriot, Y; Gross-Goupil, M; Zucali, PA; Horwich, A; Germa-Lluch, JR; ... De Santis, M; + view all (2012) 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol , 23 (1) 59 - 64. 10.1093/annonc/mdr052.

Banerji, U; van Doorn, L; Papadatos-Pastos, D; Kristeleit, R; Debnam, P; Tall, M; ... Eskens, FA; + view all (2012) A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clinical Cancer Research , 18 (9) 2687 - 2694.

Berenjeno, IM; Guillermet-Guibert, J; Pearce, W; Gray, A; Fleming, S; Vanhaesebroeck, B; (2012) Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J , 442 (1) 151 - 159. 10.1042/BJ20111741.

Butt, MA; Pye, H; Haidry, RJ; Oukrif, D; Rashid, M; Banks, MR; ... Lovat, LB; + view all (2012) ABERRANTLY GLYCOSYLATED MUC1 AS A POTENTIAL THERAPEUTIC TARGET FOR BARRETT'S WITH HIGH GRADE DYSPLASIA AND PRIMARY AND METASTATIC OESOPHAGEAL ADENOCARCINOMA. In: GUT. (pp. A301 - A301).

C

Cain, RJ; Vanhaesebroeck, B; Ridley, AJ; (2012) Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration. Int J Biochem Cell Biol , 44 (11) 1929 - 1936. 10.1016/j.biocel.2012.07.009.

Chen, C; Constantinou, A; Chester, KA; Vyas, B; Canis, K; Haslam, SM; ... Deonarain, MP; + view all (2012) Glycoengineering Approach to Half-Life Extension of Recombinant Biotherapeutics. BIOCONJUGATE CHEMISTRY , 23 (8) 1524 - 1533. 10.1021/bc200624a.

Chen, P; Tu, X; Akdemir, F; Chew, SK; Rothenfluh, A; Abrams, JM; (2012) Effectors of alcohol-induced cell killing in Drosophila. Cell Death Differ , 19 (10) 1655 - 1663. 10.1038/cdd.2012.47.

Corrie, P; Caplin, M; Reed, N; Qain, W; Lao-Sirieix, S-H; Hardy, R; ... Meyer, T; + view all (2012) Treatment of advanced neuroendocrine tumors: Results of the UKINETS and NCRI randomized phase II NET01 trial. In: Journal of Clinical Oncology. (pp. 4121 - ?).

D

Dubois, E; Jacoby, M; Blockmans, M; Pernot, E; Schiffmann, SN; Foukas, LC; ... Schurmans, S; + view all (2012) Developmental defects and rescue from glucose intolerance of a catalytically-inactive novel Ship2 mutant mouse. Cell Signal , 24 (11) 1971 - 1980. 10.1016/j.cellsig.2012.06.012.

Dunlop, MG; Dobbins, SE; Farrington, SM; Jones, AM; Palles, C; Whiffin, N; ... Houlston, RS; + view all (2012) Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet , 44 (7) 770 - 776. 10.1038/ng.2293.

E

Erturan, G; Holme, H; Cassoni, A; Tirabosco, R; Pollock, R; Briggs, T; Michelagnoli, M; (2012) CAN WE USE THE TORONTO EXTREMITY SALVAGE SCORE TO MEASURE FUNCTIONAL OUTCOME IN PAEDIATRIC DESMOID FIBROMATOSIS? PEDIATRIC BLOOD & CANCER , 59 (6) 1072 - 1073.

Erturan, G; Holme, H; Cassoni, A; Tirabosco, R; Pollock, R; Briggs, T; Michelagnoli, M; (2012) The importance of patient reported functional outcome in paediatric desmoid fibromatosis. Rare Tumors , 4 (3) e38 - ?. 10.4081/rt.2012.e38.

Erturan, G; Holme, H; Iyer, S; (2012) Corynebacterium pseudodiphtheriticum septic arthritis secondary to intra-articular injection--a case report and literature review. J Med Microbiol , 61 (Pt 6) 860 - 863. 10.1099/jmm.0.037937-0.

Erturan, G; Holme, H; Smith, R; Dodds, R; Iyer, S; (2012) Successful use of daptomycin in Panton-Valentine leucocidin positive Staphylococcus aureus paediatric osteomyelitis. Int J Surg Case Rep , 3 (7) 238 - 241. 10.1016/j.ijscr.2012.03.014.

F

Falchook, GS; Kurzrock, R; Kim, KB; Long, GV; Kefford, RF; Arkenau, TH; ... Ouellet, D; + view all (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. The Lancet , 379 (9829) 1893 - 1901. 10.1016/S0140-6736(12)60398-5.

Feng, H; Hu, B; Jarzynka, MJ; Li, Y; Keezer, S; Johns, TG; ... Cheng, SY; + view all (2012) Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proc Natl Acad Sci U S A , 109 (8) 3018 - 3023. 10.1073/pnas.1121457109.

Fenton, TR; Nathanson, D; Ponte de Albuquerque, C; Kuga, D; Iwanami, A; Dang, J; ... Furnari, FB; + view all (2012) Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A , 109 (35) 14164 - 14169. 10.1073/pnas.1211962109.

Fernandez, AF; Assenov, Y; Martin-Subero, JI; Balint, B; Siebert, R; Taniguchi, H; ... Esteller, M; + view all (2012) A DNA methylation fingerprint of 1628 human samples. Genome Res , 22 (2) 407 - 419. 10.1101/gr.119867.110.

Fizazi, K; Scher, HI; Molina, A; Logothetis, CJ; Chi, KN; Jones, RJ; ... COU-AA-301 Investigators,; + view all (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol , 13 (10) 983 - 992. 10.1016/S1470-2045(12)70379-0.

Flaherty, K; Metric Study Group,; (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. New England Journal of Medicine 10.1056/NEJMoa1203421.

Forster, M; Mendes, R; Fedele, S; (2012) Synthetic lethality and PARP-inhibitors in oral and head & neck cancer. Curr Pharm Des , 18 (34) 5431 - 5441.

G

Garelnabi, EA; Pletsas, D; Li, L; Kiakos, K; Karodia, N; Hartley, JA; ... Wheelhouse, RT; + view all (2012) Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR. ACS Med Chem Lett , 3 (12) 965 - 968. 10.1021/ml300132t.

Gerlinger, M; Rowan, AJ; Horswell, S; Larkin, J; Endesfelder, D; Gronroos, E; ... Swanton, C; + view all (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med , 366 (10) 883 - 892. 10.1056/NEJMoa1113205.

Gerlinger, M; Santos, CR; Spencer-Dene, B; Martinez, P; Endesfelder, D; Burrell, RA; ... Swanton, C; + view all (2012) Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol , 227 (2) 146 - 156. 10.1002/path.4006.

Gibson, F; Fern, L; Whelan, J; Pearce, S; Lewis, IJ; Hobin, D; Taylor, RM; (2012) A scoping exercise of favourable characteristics of professionals working in teenage and young adult cancer care: 'thinking outside of the box'. Eur J Cancer Care (Engl) , 21 (3) 330 - 339. 10.1111/j.1365-2354.2011.01322.x.

Gibson, F; Shipway, L; Barry, A; Taylor, RM; (2012) What's it like when you find eating difficult: children's and parents' experiences of food intake. Cancer Nurs , 35 (4) 265 - 277. 10.1097/NCC.0b013e31822cbd40.

Goncalves, M; Walker-Samuel, S; Johnson, SP; Pedley, RB; Lythgoe, MF; (2012) Investigating Tumour Vascular Connectivity With MRI and Independent Component Analysis. In: EUROPEAN JOURNAL OF CANCER. (pp. S205 - S205).

González-Beltrán, AN; Yong, MY; Dancey, G; Begent, R; (2012) Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy. BMC Res Notes , 5 10 - ?. 10.1186/1756-0500-5-10. Gold open access

Goodwin, R; Giaccone, G; Calvert, H; Lobbezoo, M; Eisenhauer, EA; (2012) Targeted agents: how to select the winners in preclinical and early clinical studies? Eur J Cancer , 48 (2) 170 - 178. 10.1016/j.ejca.2011.09.024.

Greco, FA; Oien, K; Erlander, M; Osborne, R; Varadhachary, G; Bridgewater, J; ... Wasan, H; + view all (2012) Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol , 23 (2) 298 - 304. 10.1093/annonc/mdr306.

H

Hartley, JA; Hamaguchi, A; Suggitt, M; Gregson, SJ; Thurston, DE; Howard, PW; (2012) DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057. Invest New Drugs , 30 (3) 950 - 958. 10.1007/s10637-011-9647-z.

Hartley, JA; Hochhauser, D; (2012) Small molecule drugs - optimizing DNA damaging agent-based therapeutics. Curr Opin Pharmacol , 12 (4) 398 - 402. 10.1016/j.coph.2012.03.008.

Ho, KK; McGuire, VA; Koo, CY; Muir, KW; de Olano, N; Maifoshie, E; ... Lam, EW; + view all (2012) Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. J Biol Chem , 287 (2) 1545 - 1555. 10.1074/jbc.M111.284224.

Holme, H; Hossain, U; Kirwan, M; Walne, A; Vulliamy, T; Dokal, I; (2012) Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia. Br J Haematol , 158 (2) 242 - 248. 10.1111/j.1365-2141.2012.09136.x.

Holme, H; Mun, KS; (2012) Postnatally diagnosed neonatal lupus. Arch Dis Child Fetal Neonatal Ed , 97 (2) F132 - ?. 10.1136/archdischild-2011-301016.

Holme, H; Westbury, C; Morgenstern, D; Erturan, G; Tirabosco, R; Pollock, R; ... Michelagnoii, M; + view all (2012) Management of paediatric desmoid fibromatosis. Archives of Disease in Childhood , 97 (Suppl 1) A86 - A86. 10.1136/archdischild-2012-301885.207.

Howie, AJ; (2012) Diagnosis of amyloid using Congo red. In: Picken, MM and Dogan, A and Herrera, G, (eds.) Amyloid and related disorders: surgical pathology and clinical correlations. (167 - 174). Springer: New York, USA.

Howie, AJ; Owen-Casey, MP; (2012) 'Apple-green birefringence' of amyloid stained by Congo red. KIDNEY INTERNATIONAL , 82 (1) 114 - 114. 10.1038/ki.2012.89.

I

Iorns, E; Ward, TM; Dean, S; Jegg, A; Thomas, D; Murugaesu, N; ... Lippman, M; + view all (2012) Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. Breast Cancer Res Treat , 135 (1) 79 - 91. 10.1007/s10549-012-2068-7.

Ip, L; Cia-Viciano, F; Spanswick, V; Pouigiannis, G; Cantley, L; Hartley, J; ... Gewinner, C; + view all (2012) Loss of the tumour suppressor inositol polyphosphate 4-phosphatase type II in ovarian cancer-implications for therapy. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE , 30 S19 - S19.

J

Jitlal, M; Khan, I; Lee, SM; Hackshaw, A; (2012) Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies. British Journal of Cancer , 107 (6) 910 - 917. 10.1038/bjc.2012.344. Green and gold open access
file

Johnson, SP; Laufer, JG; Zhang, EZ; Beard, PC; Pedley, RB; (2012) Determination of Differential Tumour Vascular Pathophysiology in Vivo by Photoacoustic Imaging. In: EUROPEAN JOURNAL OF CANCER. (pp. S186 - S187).

K

Khan, MS; Tsigani, T; Garcia-Hernandez, J; Hartley, JA; Caplin, ME; Meyer, T; (2012) Circulating tumor cells as prognostic and predictive markers in neuroendocrine tumors. In: JOURNAL OF CLINICAL ONCOLOGY.

L

Lafont, E; Dupont, R; Andrieu-Abadie, N; Okazaki, T; Schulze-Osthoff, K; Levade, T; ... Ségui, B; + view all (2012) Ordering of ceramide formation and caspase-9 activation in CD95L-induced Jurkat leukemia T cell apoptosis. Biochim Biophys Acta , 1821 (4) 684 - 693. 10.1016/j.bbalip.2012.01.012.

Laufer, J; Jathoul, A; Johnson, P; Zhang, E; Lythgoe, M; Pedley, RB; ... Beard, P; + view all (2012) In vivo photoacoustic imaging of tyrosinase expressing tumours in mice. PHOTONS PLUS ULTRASOUND: IMAGING AND SENSING 2012 , 8223 , Article ARTN 82230M. 10.1117/12.907006.

Laufer, J; Zhang, E; Treeby, B; Cox, B; Beard, P; Johnson, P; Pedley, B; (2012) In vivo preclinical photoacoustic imaging of tumor vasculature development and therapy. Journal of Biomedical Optics , 17 (5) 10.1117/1.JBO.17.5.056016.

Lee, AJ; Roylance, R; Sander, J; Gorman, P; Endesfelder, D; Kschischo, M; ... Swanton, C; + view all (2012) CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J Pathol , 226 (3) 482 - 494. 10.1002/path.2998.

Lee, M; Satam, V; Babu, B; Gregory, M; Bowerman, M; Savagian, M; ... Hartley, JA; + view all (2012) Complete analysis on the two base pair sequence recognition by Hx (p-anisylbenzimidazole)center dot pyrrole and Hx center dot imidazole pairings. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY.

Lee, M; Satam, V; Babu, B; Porte, A; Savagian, M; Lee, MD; ... Hartley, JA; + view all (2012) Synthesis and DNA binding properties of 1-(3-aminopropyl)imidazole-containing triamide f-Im*PyIm: a novel diamino polyamide designed to target 5 '-ACGCGT-3 '. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY.

Lee, SM; Khan, I; Upadhyay, S; Lewanski, C; Falk, S; Skailes, G; ... Boshoff, C; + view all (2012) First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol , 13 (11) 1161 - 1170. 10.1016/S1470-2045(12)70412-6. Gold open access

Lemech, C; Arkenau, HT; (2012) Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol , 6 53 - 66. 10.4137/CMO.S5855. Gold open access

Lemech, C; Infante, J; Arkenau, HT; (2012) The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Ther Adv Med Oncol , 4 (2) 61 - 73. 10.1177/1758834011432949. Gold open access

Lombardo, CM; Welsh, SJ; Strauss, SJ; Dale, AG; Todd, AK; Nanjunda, R; ... Neidle, S; + view all (2012) A novel series of G-quadruplex ligands with selectivity for HIF-expressing osteosarcoma and renal cancer cell lines. Bioorg Med Chem Lett , 22 (18) 5984 - 5988. 10.1016/j.bmcl.2012.07.009.

Lucas, G; Win, N; Calvert, A; Green, A; Griffin, E; Bendukidze, N; ... Massey, E; + view all (2012) Reducing the incidence of TRALI in the UK: the results of screening for donor leucocyte antibodies and the development of national guidelines. Vox Sang , 103 (1) 10 - 17. 10.1111/j.1423-0410.2011.01570.x.

M

Maharaj, L; Popat, R; Gribben, JG; Joel, S; (2012) IL-6, IL-8 and VEGF Neutralisation Restores Drug Sensitivity to Conventional and Novel Treatment Combinations in a Multiple Myeloma Bone Marrow Micro-Environment Model. In: BLOOD.

Mankia, SK; Miller, RF; Edwards, SG; Ramsay, A; Lee, SM; (2012) Highly active antiretroviral therapy alone is an effective treatment for lymphadenopathic kaposi sarcoma demonstrated by a clinical and F-18 FDG positron emission tomography/computed tomography response. Clin Oncol (R Coll Radiol) , 24 (4) 309 - 311. 10.1016/j.clon.2012.01.006.

Mankia, SK; Miller, RF; Edwards, SG; Ramsay, A; Lee, SM; (2012) The response of HIV-associated lymphadenopathic Kaposi sarcoma to highly active antiretroviral therapy evaluated by 18F-FDG PET/CT. Clin Nucl Med , 37 (7) 692 - 693. 10.1097/RLU.0b013e3182485261.

Marquardt, J; Begent, RHJ; Chester, K; Huston, JS; Bradbury, A; Scott, JK; ... Weiner, LM; + view all (2012) IBC's 23rd antibody engineering and 10th antibody therapeutics conferences, and the Annual Meeting of the Antibody Society: December 2-6, 2012, San Diego, CA. mAbs , 4 (6) 648 - 652. 10.4161/mabs.22221.

Maxwell, MJ; Tsantikos, E; Kong, AM; Vanhaesebroeck, B; Tarlinton, DM; Hibbs, ML; (2012) Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease. J Autoimmun , 38 (4) 381 - 391. 10.1016/j.jaut.2012.04.001.

McTiernan, A; Jinks, RC; Sydes, MR; Uscinska, B; Hook, JM; van Glabbeke, M; ... Whelan, JS; + view all (2012) Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. European Journal of Cancer , 48 (5) 703 - 712. 10.1016/j.ejca.2011.09.012. Green and gold open access
file

Meyer, R; Kulinskaya, E; Briassoulis, G; Taylor, RM; Cooper, M; Pathan, N; Habibi, P; (2012) The Challenge of Developing a New Predictive Formula to Estimate Energy Requirements in Ventilated Critically Ill Children. NUTRITION IN CLINICAL PRACTICE , 27 (5) 669 - 676. 10.1177/0884533612448479.

Meyer, T; Asghar, U; (2012) Reply to: "Sorafenib prolongs survival, but what happens to the symptoms?". J Hepatol , 57 (1) 223 - ?. 10.1016/j.jhep.2012.01.015.

Meyer, T; Caplin, M; Reed, N; Qian, W; Lao-Sirieix, S; Armstrong, G; ... Corrie, P; + view all (2012) TREATMENT OF ADVANCED NEUROENDOCRINE TUMOURS: FINAL RESULTS OF THE UKINETS AND NCRI RANDOMISED PHASE 2 NET01 TRIAL. In: ANNALS OF ONCOLOGY. (pp. 378 - 379).

Meyer, T; Fox, R; Bird, D; Watkinson, A; Hacking, N; Stocken, D; ... Palmer, DH; + view all (2012) TACE 2: A randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC). In: Journal of Clinical Oncology. (pp. 4150 - ?).

Meyer, T; Kirkwood, A; Gillmore, R; (2012) Reply to: "Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?". J Hepatol , 57 (1) 225 - 226. 10.1016/j.jhep.2012.02.001.

Michels, T; Shurin, GV; Naiditch, H; Sevko, A; Umansky, V; Shurin, MR; (2012) Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol , 9 (3) 292 - 300. 10.3109/1547691X.2011.642418.

Miller, J; Doss, M; McQuillen, R; Shaller, CC; Tolner, B; Yu, JQ; ... Robinson, MK; + view all (2012) Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumor Biology 1 - 11.

Miller, J; Doss, M; McQuillen, R; Shaller, CC; Tolner, B; Yu, JQ; ... Robinson, MK; + view all (2012) Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumour Biol , 33 (3) 617 - 627. 10.1007/s13277-012-0361-z.

Miranda, E; Maya Pineda, H; Öberg, D; Cherubini, G; Garate, Z; Lemoine, NR; Halldén, G; (2012) Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region. PLoS ONE , 7 (10) , Article e46617 . 10.1371/journal.pone.0046617. Green and gold open access
file

P

Palmer, D; Loembe, AB; Studeny, M; Hocke, J; Meyer, T; (2012) PHASE I STUDY OF NINTEDANIB (BIBF 1120) IN EUROPEAN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA. In: ANNALS OF ONCOLOGY. (pp. 245 - 245).

Pan, X; Hartley, JM; Hartley, JA; White, KN; Wang, Z; Bligh, SWA; (2012) Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. PHYTOMEDICINE , 19 (7) 618 - 624. 10.1016/j.phymed.2012.02.003.

Pericleous, M; Lumgair, H; Reiner, J; Marelli, L; Caplin, M; Meyer, T; Toumpanakis, C; (2012) Bronchial neuroendocrine tumors: A retrospective review of management and outcomes in 116 patients. In: JOURNAL OF CLINICAL ONCOLOGY.

Perisoglou, M; Trani, L; Strauss, S; Hartley, J; Hartley, J; Seddon, B; ... Whelan, J; + view all (2012) EFFICACY AND SAFETY OF GLUCARPIDASE FOR ROUTINE USE AFTER HIGH DOSE METHOTREXATE IN PATIENTS WITH OSTEOSARCOMA. PEDIATRIC BLOOD & CANCER , 59 (6) 1048 - 1048.

Ploquin, A; Kramar, A; Penel, N; Duhamel, A; Olmos, D; Kristeleit, RS; ... Schellens, JH; + view all (2012) Prediction of early death among patients enrolled in phase i trials: Development and validation of a new model based on platelet count and albumin. British Journal of Cancer , 107 (7) 1025 - 1030. 10.1038/bjc.2012.371.

R

Raja, FA; Hook, JM; Ledermann, JA; (2012) Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. Cancer Treat Rev , 38 (6) 662 - 672. 10.1016/j.ctrv.2011.11.009.

Rajkumar, VS; Boxer, G; Robson, M; Muddle, J; Papastavrou, Y; Pedley, RB; (2012) A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma. Tumour Biol , 33 (6) 2019 - 2029. 10.1007/s13277-012-0461-9.

Ramage, JK; Ahmed, A; Ardill, J; Bax, N; Breen, DJ; Caplin, ME; ... Grossman, AB; + view all (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). GUT , 61 (1) 6 - 32. 10.1136/gutjnl-2011-300831.

Rossi, A; Di Maio, M; Chiodini, P; Rudd, RM; Okamoto, H; Skarlos, DV; ... Lee, SM; + view all (2012) Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol , 30 (14) 1692 - 1698. 10.1200/JCO.2011.40.4905.

S

Satam, V; Babu, B; Chavda, S; Savagian, M; Sjoholm, R; Tzou, S; ... Lee, M; + view all (2012) Novel diamino imidazole and pyrrole-containing polyamides: Synthesis and DNA binding studies of mono- and diamino-phenyl-ImPy*Im polyamides designed to target 5'-ACGCGT-3'. Bioorg Med Chem , 20 (2) 693 - 701. 10.1016/j.bmc.2011.12.010.

Satam, V; Babu, B; Chavda, S; Savagian, M; Sjoholm, R; Tzou, S; ... Lee, M; + view all (2012) Novel diamino imidazole and pyrrole-containing polyamides: Synthesis and DNA binding studies of mono- and diamino-phenyl-ImPy*Im polyamides designed to target 5 '-ACGCGT-3 ' (vol 20, pg 693, 2012). BIOORGANIC & MEDICINAL CHEMISTRY , 20 (15) 4881 - 4881. 10.1016/j.bmc.2012.06.037.

Satam, V; Babu, B; Porte, A; Savagian, M; Lee, M; Smeltzer, T; ... Lee, M; + view all (2012) Synthesis and DNA binding properties of 1-(3-aminopropyl)-imidazole-containing triamide f-Im*PyIm: a novel diamino polyamide designed to target 5'-ACGCGT-3'. Bioorg Med Chem Lett , 22 (18) 5898 - 5902. 10.1016/j.bmcl.2012.07.071.

Sengerová, B; Allerston, CK; Abu, M; Lee, SY; Hartley, J; Kiakos, K; ... McHugh, PJ; + view all (2012) Characterization of the human SNM1A and SNM1B/Apollo DNA repair exonucleases. Journal of Biological Chemistry , 287 (31) 26254 -26267. 10.1074/jbc.M112.367243. Green and gold open access
file

Sevko, A; Kremer, V; Falk, C; Umansky, L; Shurin, MR; Shurin, GV; Umansky, V; (2012) Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J Immunotoxicol , 9 (3) 275 - 281. 10.3109/1547691X.2012.655343.

Silini, A; Ghilardi, C; Figini, S; Sangalli, F; Fruscio, R; Dahse, R; ... Bani, M; + view all (2012) Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol Life Sci , 69 (7) 1167 - 1178. 10.1007/s00018-011-0862-8.

Spanswick, VJ; Lowe, HL; Newton, C; Bingham, JP; Bagnobianchi, A; Kiakos, K; ... Hartley, JA; + view all (2012) Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer , 12 , Article 436. 10.1186/1471-2407-12-436. Green and gold open access
file

T

Toumpanakis, C; Baneke, A; Pericleous, M; Meyer, T; Caplin, ME; (2012) Diagnostic and therapeutic outcomes in goblet cell appendiceal neuroendocrine tumors. In: JOURNAL OF CLINICAL ONCOLOGY.

Tsochatzis, EA; Meyer, T; Burroughs, AK; (2012) Hepatocellular carcinoma. N.Engl.J.Med. , 366 (1) 92 - 93. 10.1056/NEJMc1112501#SA2.

Tzenaki, N; Andreou, M; Stratigi, K; Vergetaki, A; Makrigiannakis, A; Vanhaesebroeck, B; Papakonstanti, EA; (2012) High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation. FASEB J , 26 (6) 2498 - 2508. 10.1096/fj.11-198192.

U

Umansky, V; Sevko, A; (2012) Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol , 22 (4) 319 - 326. 10.1016/j.semcancer.2012.02.003.

Umansky, V; Sevko, A; (2012) Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother , 61 (2) 275 - 282. 10.1007/s00262-011-1164-6.

V

Vanhaesebroeck, B; Stephens, L; Hawkins, P; (2012) PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol , 13 (3) 195 - 203. 10.1038/nrm3290.

Vincenzi, B; Santini, D; Schiavon, G; Frezza, AM; Dileo, P; Silletta, M; ... Tonini, G; + view all (2012) Bone metastases in soft tissue sarcoma patients: A survey of natural, prognostic value, and treatment. In: JOURNAL OF CLINICAL ONCOLOGY.

W

Walker-Samuel, S; Johnson, SP; Pedley, B; Lythgoe, MF; Golay, X; (2012) Extracranial measurements of amide proton transfer using exchange-modulated point-resolved spectroscopy (EXPRESS). NMR Biomed , 25 (6) 829 - 834. 10.1002/nbm.1798.

Walker-Samuel, S; Ramasawmy, R; Wells, J; Siow, B; Johnson, SP; Pedley, RB; Lythgoe, MF; (2012) Non-invasive Measurement of Tumour Interstitial Fluid Pressure Using Magnetic Resonance Imaging. In: EUROPEAN JOURNAL OF CANCER. (pp. S96 - S96).

Weatherstone, K; Meyer, T; (2012) Streptozocin-based chemotherapy is not history in neuroendocrine tumours. Targeted Oncology , 7 (3) 161 - 168. 10.1007/s11523-012-0224-y.

Whelan, J; McTiernan, A; Cooper, N; Wong, YK; Francis, M; Vernon, S; Strauss, SJ; (2012) Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer , 131 (4) E508 - E517. 10.1002/ijc.26426.

Whelan, JS; Jinks, RC; McTiernan, A; Sydes, MR; Hook, JM; Trani, L; ... Gelderblom, H; + view all (2012) Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol , 23 (6) 1607 - 1616. 10.1093/annonc/mdr491.

Whitehead, MA; Bombardieri, M; Pitzalis, C; Vanhaesebroeck, B; (2012) Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter. Biochem J , 443 (3) 857 - 867. 10.1042/BJ20112214.

Winckworth, LC; Holme, H; (2012) Question 3: Inhaled mannitol improves lung function in patients with cystic fibrosis. Arch Dis Child , 97 (11) 1003 - 1006. 10.1136/archdischild-2012-302513.

Windsor, RE; Strauss, SJ; Kallis, C; Wood, NE; Whelan, JS; (2012) Germline Genetic Polymorphisms May Influence Chemotherapy Response and Disease Outcome in Osteosarcoma. CANCER , 118 (7) 1856 - 1867. 10.1002/cncr.26472.

Windsor, RE; Strauss, SJ; Whelan, JS; Kallis, C; Wood, NE; (2012) Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: A pilot study. Cancer , 118 (7) 1856 - 1867. 10.1002/cncr.26472.

Y

Yang, J; Staples, O; Thomas, LW; Briston, T; Robson, M; Poon, E; ... Ashcroft, M; + view all (2012) Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. J Clin Invest , 122 (2) 600 - 611. 10.1172/JCI58780.

Z

Zwaenepoel, O; Tzenaki, N; Vergetaki, A; Makrigiannakis, A; Vanhaesebroeck, B; Papakonstanti, EA; (2012) Functional CSF-1 receptors are located at the nuclear envelope and activated via the p110δ isoform of PI 3-kinase. FASEB J , 26 (2) 691 - 706. 10.1096/fj.11-189753.

This list was generated on Sun Aug 31 03:17:29 2014 BST.